Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy demonstrates impressive efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). ......
小提示:本篇文献需要登录阅读全文,点击跳转登录